Emerging molecular markers of cancer

By D. Sidransky. Nature Reviews. Cancer, 2002

672 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c62d61a49c3cdd0c2b83b6c2bd7d38a5e37de197

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Multiplexed electrical detection of cancer markers with nanowire sensor arrays (2005, background): “4 mM dCTP and (6) a mixture of all four dNTPs each at 0.”
The fundamental role of epigenetic events in cancer (2002, result): “The results of some of these studies indicate that this approach might offer some promise for early diagnosis and/or risk assessmen”
Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles (2009, background): “Studies using molecular-based biomarkers in blood or urine to detect the progress of malignant tumors have mainly focused on altered DNA methylation or mutation, or on changes in the RNA or protein levels (Sidransky 2002).”
An autonomous molecular computer for logical control of gene expression (2004, methodology): “As a proof of principle we programmed the computer to identify and analyse mRNA of disease-related gene”
Radical causes of cancer (2003, background): “The analysis of cancer-related gene fragments in serum or other bodily specimens, such as stools, might also provide useful intermediate biomarker”
Cancer genes and the pathways they control (2004, background): “Perhaps knowledge of the genes altered in cancer will provide the basis for new generations of diagnostic tests, employing target-specific imaging or analysis of body fluid samples ex vivo that will make early detection approaches feasibl”
Multimodal biomedical AI (2022, background): “Genetic and molecular markers of malignant tumors have been integrated into clinical practice 5,6 , with the US Food and Drug Administration (FDA) providing approval for several companion diagnostic devices and nucleic acid-based tests 7,8 .”
The genetics and genomics of cancer (2003, positive): “Sensitive and non-invasive methods of early diagnosis may be developed from the detection of cancer-specific DNA mutations or abnormal DNA methylation patterns in readily accessible body fluid”
Salivary Transcriptome Diagnostics for Oral Cancer Detection (2004, background): “Changes that arise exclusively or preferentially in cancer, compared with normal tissue of the same origin, can be used as molecular biomarkers (4).”
CpG island methylator phenotype in cancer (2004, background): “Indeed, DNA methylation is proving to be a useful marker of disease risk, activity and prognosis in various malignancie”
Nanotechnology for Early Cancer Detection (2010, neutral): “[1,23,24]”
Biomarkers in Cancer Staging, Prognosis and Treatment Selection (2005, background): “Increased serum DNA concentrations are associated with cancer (principally metastatic cancer) and with other conditions such as sepsis and autoimmune diseas”
Early detection: The power and the promise of DNA methylation markers (2003, neutral): “Cancer-specific DNA methylation patterns can be found in detached tumour cells in bodily fluids and biopsies, and they can be detected in free-floating DNA that is released from dead cancer cell”